Long-term Effects Of Tirofiban Similar To Those Of Abciximab In Patients Undergoing Coronary-artery Angioplasty (p 355)July 31, 2002A follow-up study in this week's issue of THE LANCET helps to clarify the differences between two similar drugs in terms of their benefits for patients who undergo angioplasty for narrowed coronary arteries (the arteries that supply the heart with blood). Platelet glycoprotein IIb/IIIa inhibitors reduce the clumping together of platelets in the blood, which can lead to complications during procedures to open narrowed arteries. Tirofiban and abciximab are two such drugs, but each blocks platelet clumping in a slightly different way. Researchers around the world are trying to work out the relevance of these differences with respect to patients' health. Last year, the TARGET investigators showed that abciximab was significantly better than tirofiban at preventing death, heart attacks, and repeated surgery among 4809 patients within 30 days after they had undergone a coronary-artery angioplasty with stent placement. These investigators, led by Dr David Moliterno from the Cleveland Clinic Foundation, Ohio, USA, now report follow-up data from the TARGET study, which they obtained 6 months after angioplasty. Surprisingly, they found that 14·8% of the patients taking tirofiban had died, had a heart attack, or had repeat surgery, compared with 14·3% of those who took abciximab. In other words, the drugs were about equally effective in terms of preventing these longer-term events. David Moliterno comments: "As studied, abciximab was more protective against a heart attack occurring during, or immediately following, angioplasty. Yet the two drugs were associated with similarly low rates of death and renarrowing of the heart's arteries at 6 months. Our conclusion is that while the more expensive drug (abciximab) is better 'up front', it provides little long-term advantage compared with tirofiban." Lancet |
|||||||||||||||||||||
| Related Angioplasty Current Events and Angioplasty News Articles Your Own Stem Cells Can Treat Heart Disease The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. The heart attack myth: Study establishes that women do have same the heart attack symptoms as men The gender difference between men and women is a lot smaller than we've been led to believe when it comes to heart attack symptoms. Lifestyle changes remain important in fighting peripheral arterial disease Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. Study questions need for routine intervention in patients with renovascular disease Some invasive procedures that are becoming increasingly common as a first line of treatment for patients diagnosed with narrowed arteries in and around the kidneys may not be necessary. Designing drugs and their antidotes together improves patient care Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. Pre-hospital organization: The first links in the chain of survival for heart attack patients Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%. Stent for life initiative Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina). New strategies for reperfusion therapy A new trial has begun in order to ascertain once and for all whether the best strategy for patients who cannot receive P-PCI is early fibrinolysis, together with mandated angiography. More Angioplasty Current Events and Angioplasty News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||